A Mayo Clinic-led team of researchers is solving one of the most frustrating aspects of genetic cancer screening – results that give zero guidance to patients on whether they are at elevated risk.

The 1-year PFS rate was 75.2%, with a median PFS of 21.0 months, aligning with previous trials and highlighting olaparib's efficacy in maintaining remission in patients with HRD-positive ...

BReast CAncer (BRCA)1 and BRCA2 gene pathogenic variants account for most hereditary breast cancers (BC). Identification of BRCA mutations can significantly influence both prognosis and treatment ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...